T-3262、NY-198、氟罗沙星（AM-833；RO 23-6240）及其他新型喹诺酮类药物对临床分离沙眼衣原体菌株的体外活性。
In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
作者信息
Maeda H, Fujii A, Nakata K, Arakawa S, Kamidono S
机构信息
Department of Urology, School of Medicine, Kobe University, Japan.
出版信息
Antimicrob Agents Chemother. 1988 Jul;32(7):1080-1. doi: 10.1128/AAC.32.7.1080.
Abstract
The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chlamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 microgram/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 micrograms/ml, respectively.
摘要
评估了三种新开发的喹诺酮类药物（T-3262、NY-198和氟罗沙星[AM-833；RO 23-6240]）对10株临床分离沙眼衣原体的体外活性，并与其他喹诺酮类药物和米诺环素进行了比较。T-3262（90%受试分离株的MIC为0.1微克/毫升）是喹诺酮类药物中活性最强的。NY-198和氟罗沙星对90%分离株的MIC分别为3.13和62.5微克/毫升。
相似文献
1
In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
Antimicrob Agents Chemother. 1988 Jul;32(7):1080-1. doi: 10.1128/AAC.32.7.1080.
2
Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Chemotherapy. 1997 Jul-Aug;43(4):239-44. doi: 10.1159/000239573.
3
In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.
Antimicrob Agents Chemother. 1988 Nov;32(11):1735-7. doi: 10.1128/AAC.32.11.1735.
4
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
5
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Diagn Microbiol Infect Dis. 1995 Apr;21(4):209-13. doi: 10.1016/0732-8893(94)00061-z.
6
In vitro activities of five quinolones against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
7
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.
8
In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
Chemotherapy. 1988;34(5):401-10. doi: 10.1159/000238599.
9
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Antimicrob Agents Chemother. 1997 Jun;41(6):1331-4. doi: 10.1128/AAC.41.6.1331.
10
In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains.
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):87S-88S. doi: 10.1016/0732-8893(89)90072-2.
引用本文的文献
1
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
2
In vitro activities of temafloxacin (A-62254) and four other antibiotics against Chlamydia trachomatis.
Antimicrob Agents Chemother. 1989 Jan;33(1):118-9. doi: 10.1128/AAC.33.1.118.
3
Fluoroquinolone antimicrobial agents.
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
4
Quinolones in urology.
Urol Res. 1989;17(2):117-24. doi: 10.1007/BF00262033.
5
Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.
Antimicrob Agents Chemother. 1989 Oct;33(10):1774-7. doi: 10.1128/AAC.33.10.1774.
6
In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.
Antimicrob Agents Chemother. 1990 Jun;34(6):971-3. doi: 10.1128/AAC.34.6.971.
7
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009.
8
Fleroxacin clinical pharmacokinetics.
Clin Pharmacokinet. 1992 Feb;22(2):116-31. doi: 10.2165/00003088-199222020-00003.
9
In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.
Antimicrob Agents Chemother. 1992 Jan;36(1):188-90. doi: 10.1128/AAC.36.1.188.
本文引用的文献
1
Epidemiology of chlamydial infection of the human genital tract: evidence for the existence of latent infections.
Eur J Clin Microbiol. 1982 Apr;1(2):69-75. doi: 10.1007/BF02014194.
2
Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.
Antimicrob Agents Chemother. 1984 Jul;26(1):13-6. doi: 10.1128/AAC.26.1.13.
3
Sexually transmitted organisms and infertility: the proof of the pudding.
Sex Transm Dis. 1984 Apr-Jun;11(2):113-6.
4
Genital infection in men.
Br Med Bull. 1983 Apr;39(2):133-7. doi: 10.1093/oxfordjournals.bmb.a071804.
5
In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
Antimicrob Agents Chemother. 1984 Jan;25(1):123-4. doi: 10.1128/AAC.25.1.123.
6
Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis.
J Urol. 1985 Oct;134(4):691-3. doi: 10.1016/s0022-5347(17)47387-3.
7
Activities of new quinoline derivatives against genital pathogens.
Antimicrob Agents Chemother. 1985 Jan;27(1):76-8. doi: 10.1128/AAC.27.1.76.
8
Failure of norfloxacin to eradicate Chlamydia trachomatis in nongonococcal urethritis.
Antimicrob Agents Chemother. 1986 Oct;30(4):594-7. doi: 10.1128/AAC.30.4.594.
9
Treatment of nongonococcal urethritis with ciprofloxacin.
Am J Med. 1987 Apr 27;82(4A):311-6.
10
Ofloxacin: therapeutic results in Chlamydia trachomatis urethritis.
Infection. 1986;14 Suppl 4:S316-7. doi: 10.1007/BF01661306.
Zotero 插件